Table 2.
Patient Characteristics.
| Characteristics | No. | % | Characteristics | No. | % |
|---|---|---|---|---|---|
| Age at Diagnosis (Years) | Primary Tumor Location | ||||
| Median | 60 | - | Nasopharynx | 14 | 8.2% |
| ≥60 | 85 | 50.0% | Oropharynx | 68 | 40.0% |
| <60 | 85 | 50.0% | Oral Cavity | 40 | 23.5% |
| Hypopharynx | 10 | 5.9% | |||
| Gender | Larynx | 27 | 15.9% | ||
| Male | 123 | 72.4% | Sino–Nasal | 6 | 3.5% |
| Female | 47 | 27.6% | Unknown | 5 | 3.0% |
| Race | Disease Stage at Time of Diagnosis |
||||
| Caucasian | 142 | 83.5% | |||
| African American | 19 | 11.2% | |||
| Other | 9 | 5.3% | Cancer Stage | ||
| I | 21 | 12.4% | |||
| ETOH Status | II | 30 | 17.6% | ||
| Never | 92 | 54.1% | III | 37 | 21.8% |
| Former | 36 | 21.2% | IV | 82 | 48.2% |
| Active | 72 | 24.7% | |||
| Cancer Stage IV | |||||
| Smoking Status | IVA | 50 | 29.4% | ||
| Never | 48 | 28.2% | IVB | 22 | 12.9% |
| Former | 50 | 29.4% | IVC | 9 | 5.3% |
| Active | 72 | 42.4% | |||
| N Stage | |||||
| HPV and/or p16 | N0 | 47 | 27.6% | ||
| Negative | 61 | 35.9% | N1 | 35 | 20.6% |
| Positive | 61 | 35.9% | N2 | 69 | 40.6% |
| Not Tested | 48 | 28.2% | N3 | 19 | 11.2% |
| tDNA Tissue | Disease Status | ||||
| Source | At Last Visit | ||||
| Primary Tumor | 92 | 54.1% | No Evidence of Disease | 61 | 35.9% |
| Regional Lymph Node | 11 | 6.5% | Locoregional | 44 | 25.9% |
| Metastatic Lesion | 11 | 6.5% | Metastatic (only) | 17 | 10.0% |
| Recurrence | 25 | 14.7% | Locoregional and Metastatic | 48 | 28.2% |
ctDNA, circulating tumor DNA; tDNA, tumor tissue DNA.